Characterization of tumour mutation burden in patients with non‐small cell lung cancer and interstitial lung disease

The efficacy expectation of immune checkpoint inhibitors against NSCLC in patients with ILD seems to be high because these populations are supposed to have high TMB. However, information about the characterization of TMB in patients with NSCLC and ILD is limited. Therefore, this study aimed to evaluate TMB in samples of NSCLC with ILD and clarify factors that influence TMB values.

[1]  T. Maeyama,et al.  Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis , 2018, Thoracic cancer.

[2]  A. Otsuka,et al.  Deleterious Pulmonary Surfactant System Gene Mutations in Lung Adenocarcinomas Associated With Usual Interstitial Pneumonia. , 2018, JCO precision oncology.

[3]  Nikolaus Schultz,et al.  Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers , 2018, Clinical Cancer Research.

[4]  Young Hak Kim,et al.  Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease , 2018, Thoracic cancer.

[5]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[6]  T. Morimoto,et al.  A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. , 2017, Lung cancer.

[7]  K. Kinzler,et al.  Evaluating the evaluation of cancer driver genes , 2016, Proceedings of the National Academy of Sciences.

[8]  Kui Wu,et al.  Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma , 2016, Oncotarget.

[9]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[10]  Shandra L. Protzko,et al.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.

[11]  Nicholas B. Larson,et al.  PurBayes: estimating tumor cellularity and subclonality in next-generation sequencing data , 2013, Bioinform..

[12]  T. Higami,et al.  Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? , 2008, The Journal of thoracic and cardiovascular surgery.

[13]  David A Lynch,et al.  High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. , 2005, American journal of respiratory and critical care medicine.

[14]  D. Spandidos,et al.  MYCL1, FHIT, SPARC, p16INK4 and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis , 2002, Journal of cellular and molecular medicine.